INDIANAPOLIS, February 09,2017 /PRNewswire/ --
The board of directors of Eli Lilly and Company (NYSE: LLY) has
elected Carolyn R. Bertozzi, Ph.D.,
as a new member, effective Feb. 10,
2017. As a member of Lilly's board, she will serve on the
Science and Technology and Public Policy and Compliance Committees
of the board.
Professor Bertozzi is the Anne T. and Robert M. Bass Professor
of Chemistry and Professor of Chemical & Systems Biology and
Radiology at Stanford University, and
an Investigator of the Howard Hughes Medical Institute. She
completed her undergraduate degree in chemistry from Harvard University in 1988 and her doctorate in
chemistry from UC Berkeley in 1993. After completing postdoctoral
work at UCSF in the field of cellular immunology, she joined the UC
Berkeley faculty in 1996. In June
2015, she joined the faculty at Stanford University coincident with the launch of
Stanford's ChEM-H institute.
"We are very pleased to welcome Carolyn
Bertozzi to the Lilly board," said John C. Lechleiter,
Ph.D., chairman of the board of directors.
"Professor Bertozzi, with her broad scientific expertise
and solid record of accomplishment, along with her understanding of
the biopharmaceutical industry, will contribute greatly
to our board and our company as we seek to advance Lilly's
pipeline of potential new medicines to benefit patients and our
other key stakeholders."
Professor Bertozzi's research interests span the disciplines of
chemistry and biology with an emphasis on studies of cell surface
glycosylation pertinent to disease states. Her lab focuses on
profiling changes in cell surface glycosylation associated with
cancer, inflammation and bacterial infection, and exploiting this
information for development of diagnostic and therapeutic
approaches, most recently in the area of immuno-oncology. She has
been recognized with many honors and awards for her research
accomplishments. She is an elected member of the Institute of
Medicine, National Academy of Sciences, and American Academy of
Arts and Sciences. She has been awarded the Lemelson-MIT Prize, the
Heinrich Wieland Prize, and a MacArthur Foundation Fellowship,
among many others.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with
discovery to make life better for people around the world. We were
founded more than a century ago by a man committed to creating
high-quality medicines that meet real needs, and today we remain
true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to
those who need them, improve the understanding and management of
disease, and give back to communities through philanthropy and
volunteerism. To learn more about Lilly, please visit us at
www.lilly.com and www.lilly.com/newsroom/social-channels.
C-LLY
Refer to: Edward Sagebiel;
egs@lilly.com ; 317-985-6303
This is a disclosure announcement from PR Newswire.